

# Carsten Schwarz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8844060/publications.pdf>

Version: 2024-02-01

44  
papers

1,005  
citations

567281

15  
h-index

454955

30  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 136-142.	0.7	10
2	Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 228-233.	0.7	21
3	Genetic diversification of persistent <i>Mycobacterium abscessus</i> within cystic fibrosis patients. <i>Virulence</i> , 2021, 12, 2415-2429.	4.4	14
4	Biomarkers for the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis: A Systematic Review and Meta-Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1909-1930.e4.	3.8	15
5	Clinical impact of levofloxacin inhalation solution in cystic fibrosis patients in a real-world setting. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 1035-1039.	0.7	7
6	CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis. <i>Pulmonary Therapy</i> , 2021, 7, 377-393.	2.2	11
7	Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging. <i>Pharmaceutics</i> , 2021, 13, 2051.	4.5	3
8	Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 99-107.	0.7	46
9	GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). <i>Journal of Cystic Fibrosis</i> , 2020, 19, 292-298.	0.7	11
10	Urban Life as Risk Factor for Aspergillosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 601834.	3.9	6
11	Risk factors for respiratory <i>Aspergillus fumigatus</i> in German Cystic Fibrosis patients and impact on lung function. <i>Scientific Reports</i> , 2020, 10, 18999.	3.3	30
12	Mutation on <i>lysX</i> from <i>Mycobacterium avium hominissuis</i> impacts the host-pathogen interaction and virulence phenotype. <i>Virulence</i> , 2020, 11, 132-144.	4.4	11
13	Prospective Evaluation of <i>Aspergillus fumigatus</i> -Specific IgG in Patients With Cystic Fibrosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 602836.	3.9	8
14	Frequent Pet Contact as Risk Factor for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 601821.	3.9	5
15	Biatrial Remodeling in Patients with Cystic Fibrosis. <i>Journal of Clinical Medicine</i> , 2019, 8, 1141.	2.4	3
16	Clinical manifestations and risk factors of arthropathy in cystic fibrosis. <i>Respiratory Medicine</i> , 2019, 147, 66-71.	2.9	11
17	Type I interferon induced by TLR2-TLR4-MyD88-TRIF-IRF3 controls <i>Mycobacterium abscessus</i> subsp. <i>abscessus</i> persistence in murine macrophages via nitric oxide. <i>International Journal of Medical Microbiology</i> , 2019, 309, 307-318.	3.6	16
18	Long needed guidelines: Referral to transplant for cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 305-306.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against <i>Candida albicans</i> . <i>Cell</i> , 2019, 176, 1340-1355.e15.	28.9	321
20	Risk of piperacillin-induced hemolytic anemia in patients with cystic fibrosis and antipseudomonal treatment: a prospective observational study. <i>Transfusion</i> , 2019, 59, 3746-3754.	1.6	9
21	Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 227-232.	0.7	26
22	Environmental <i>Mycobacterium avium</i> subsp. <i>hominissuis</i> have a higher probability to act as a recipient in conjugation than clinical strains. <i>Plasmid</i> , 2018, 95, 28-35.	1.4	7
23	Fungal Respiratory Infections in Cystic Fibrosis (CF): Recent Progress and Future Research Agenda. <i>Mycopathologia</i> , 2018, 183, 1-5.	3.1	9
24	Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections. <i>Mycopathologia</i> , 2018, 183, 213-226.	3.1	17
25	Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis. <i>Medical Mycology</i> , 2018, 56, S42-S59.	0.7	27
26	Organization of Patient Management and Fungal Epidemiology in Cystic Fibrosis. <i>Mycopathologia</i> , 2018, 183, 7-19.	3.1	32
27	Mepolizumab—a novel option for the treatment of hypereosinophilic syndrome in childhood. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 28-33.	2.6	13
28	Invasive Pulmonary Fungal Infections in Cystic Fibrosis. <i>Mycopathologia</i> , 2018, 183, 33-43.	3.1	27
29	<i>Aspergillus</i> Bronchitis in Patients with Cystic Fibrosis. <i>Mycopathologia</i> , 2018, 183, 61-69.	3.1	65
30	Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis. <i>Mycopathologia</i> , 2018, 183, 21-32.	3.1	43
31	Prospective multicenter German study on pulmonary colonization with <i>Scenedosporium</i> / <i>Lomentospora</i> species in cystic fibrosis: Epidemiology and new association factors. <i>PLoS ONE</i> , 2017, 12, e0171485.	2.5	47
32	Allergic bronchopulmonary aspergillosis is associated with pet ownership in cystic fibrosis. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 597-603.	2.6	15
33	Piperacillin-induced mild haemolytic anaemia in a 44-year-old patient with cystic fibrosis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216937.	0.5	8
34	Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0158193.	2.5	2
35	Cystic fibrosis in Europe: patients live longer but are we ready?. <i>European Respiratory Journal</i> , 2015, 46, 11-12.	6.7	11
36	Colobreathe® for the Treatment of Cystic Fibrosis-Associated Pulmonary Infections. <i>Pulmonary Therapy</i> , 2015, 1, 19-30.	2.2	13

#	ARTICLE	IF	CITATIONS
37	Different approaches to evaluate patient experience and satisfaction in CF centres. <i>Journal of Cystic Fibrosis</i> , 2015, 14, E19-E20.	0.7	0
38	Patient experience in cystic fibrosis care: Development of a disease-specific questionnaire. <i>Chronic Illness</i> , 2015, 11, 108-125.	1.5	10
39	<i>Arxula adenivorans</i> causing invasive pulmonary mycosis and fungaemia in cystic fibrosis. <i>Lancet, The</i> , 2015, 385, 1476.	13.7	10
40	Cystic fibrosis (CF) care through the patients' eyes – A nationwide survey on experience and satisfaction with services using a disease-specific questionnaire. <i>Respiratory Medicine</i> , 2015, 109, 79-87.	2.9	7
41	<i>Scedosporium apiospermum</i> : a fungal pathogen causing pneumonia in a patient with cystic fibrosis. <i>JMM Case Reports</i> , 2015, 2, .	1.3	10
42	Hypersensitivity to antibiotics in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 205-211.	0.7	45
43	Hypersensitivity to parenteral antibiotics in patients with cystic fibrosis. <i>Clinical and Translational Allergy</i> , 2014, 4, P66.	3.2	0
44	Zystische Fibrose: Mukoviszidose ist längst keine Kinderkrankheit mehr. , 0, , .		0